



## Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: A meta-analysis of randomized controlled trials

Vishal Ranpura, Sanjaykumar Hapani, Jeff Chuang & Shenhong Wu

**To cite this article:** Vishal Ranpura, Sanjaykumar Hapani, Jeff Chuang & Shenhong Wu (2010) Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: A meta-analysis of randomized controlled trials, Acta Oncologica, 49:3, 287-297, DOI: [10.3109/02841860903524396](https://doi.org/10.3109/02841860903524396)

**To link to this article:** <https://doi.org/10.3109/02841860903524396>



Published online: 16 Feb 2010.



Submit your article to this journal [↗](#)



Article views: 3579



View related articles [↗](#)



Citing articles: 25 View citing articles [↗](#)

REVIEW ARTICLE

## Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: A meta-analysis of randomized controlled trials

VISHAL RANPURA, SANJAYKUMAR HAPANI, JEFF CHUANG & SHENHONG WU

Division of Hematology and Medical Oncology, Department of Medicine, Stony Brook University Medical Center, Stony Brook, New York, USA

### Abstract

**Background.** The risk of cardiovascular toxicities is a serious concern with the increased application of angiogenesis inhibitors in current cancer therapy. Arterial thromboembolic events (ATE) were associated with bevacizumab, an antibody against vascular endothelial growth factor. To determine the risk of ATE including cardiac ischemia and stroke, a systematic review and meta-analysis of published randomized controlled trials (RCTs) was performed. **Methods.** We searched the databases of PubMed, Web of Science, and American Society of Clinical Oncology conferences to identify relevant clinical trials up to May, 2009. Eligible studies included prospective RCTs in which bevacizumab was compared to a control concurrently in combination with standard anti-neoplastic therapy. Summary incidence rates, relative risks (RRs), and 95% confidence intervals (CIs) were calculated using random-effects or fixed-effects models. **Results.** A total of 12 617 patients with a variety of advanced solid tumors from 20 RCTs were included for analysis. The incidences of all-grade and high-grade ATE in patients receiving bevacizumab were 3.3% (95% CI, 2.0–5.6%) and 2.0% (95% CI, 1.7–2.5) respectively. Patients treated with bevacizumab had a significantly increased risk of ATE with an RR of 1.44 (95% CI, 1.08–1.91;  $p=0.013$ ) compared with controls. The risk similarly increased for bevacizumab at 2.5 and 5 mg/kg/week; in addition, significantly increased risks were observed in patients with renal cell cancer (RR, 3.72, 95% CI, 1.15–12.04;  $p=0.029$ ) and colorectal cancer (RR, 1.89, 95% CI, 1.28–2.80,  $p=0.001$ ). Notably, the risk of high-grade cardiac ischemia with bevacizumab was significantly higher than controls with an RR of 2.14 (95% CI, 1.12–4.08,  $p=0.021$ ); however, the risk of ischemic stroke with bevacizumab was not significantly different from controls (RR, 1.37, 95% CI, 0.67–2.79,  $p=0.39$ ). **Discussion.** Treatment with bevacizumab may significantly increase the risk of cardiac ischemic events in cancer patients.

Angiogenesis plays important role in tumor progression and metastasis, and is a focal topic in the field of cancer research [1–3]. This process is mainly driven by vascular endothelial growth factor (VEGF), and hence to disrupt its signaling has become a major approach in current cancer therapeutics [3,4]. Bevacizumab (Avastin, Genentech Inc, South San Francisco), a recombinant humanized monoclonal antibody against VEGF, has been approved by the Food and Drug administration of USA for the treatment of many advanced solid tumors including colorectal cancer (CRC), non-small cell lung cancer (NSCLC), breast cancer, glioblastoma, and recently

renal cell cancer (RCC) [5]. Currently, the use of bevacizumab in other advanced cancers as well as neoadjuvant and adjuvant therapy in patients with earlier stage diseases is also undergoing extensive evaluation [6–9].

Bevacizumab treatment has been associated with the occurrence of arterial thrombotic events (ATE) [10]. In the pivotal placebo-controlled phase III trial for metastatic CRC by Hurwitz and colleagues, 20 of 393 patients treated with bevacizumab developed ATE as compared to five of 397 patients in controls [11]. In 2007, a pooled analysis of five randomized controlled trials (RCTs) that included a total of

1 745 patients with metastatic CRC, breast, NSCLC showed that increased risk of ATE was found in the patients treated with bevacizumab in combination with chemotherapy compared to chemotherapy alone (risk ratio, 2.0; 95% CI, 1.05–3.75,  $p=0.031$ ) [12]. The incidence of ATE events was 3.8% in bevacizumab group as compared to 1.7% in chemotherapy alone group.

However, this study is limited by a small number of RCTs (only five trials) included for analysis. The overall risk of ATE remains unclear for general cancer patients with a variety of tumor types. Also, the relationship between bevacizumab dose and the risk of ATE needs to be defined. Because ATE includes the involvement of several different arteries such as coronary artery and cerebral artery, questions remain regarding the effect of bevacizumab on the risk of specific type of ATE such as cardiac ischemia or stroke. In order to understand these issues, we performed a systematic review and meta-analysis of published RCTs to determine the impact of bevacizumab on the occurrence of ATE in cancer patients.

## Methods

### *Data source*

We performed a comprehensive search of citations from PubMed between January, 1966, and May, 2009, using the keywords “bevacizumab”, “avastin”, and “cancer”. The search was limited to randomized clinical trials. The search strategy also used the text terms “arterial thrombosis”, “arterial thromboembolic events”, “angiogenesis”, “thrombosis” and “vascular endothelial growth factor” to identify relevant information. Abstracts and virtual meeting presentations from the American Society of Clinical Oncology conferences held between January, 2000, and May, 2009, were also searched to identify relevant RCTs. An independent search using the citation database Web of Science was done to ensure that all relevant clinical trials were included in the meta-analysis.

We also reviewed FDA submission documents, the updated manufacturer’s package insert. The reference lists of identified articles were examined for additional publications. We reviewed each publication; when duplicate publications were identified, only the most recent or complete report of clinical trials was included. The safety data from the manufacturer’s updated package insert of bevacizumab was also reviewed to identify relevant information, and considered to be the most recent for our analysis. Efforts were also made to contact the investigators and the manufacturer of bevacizumab when relevant data was not clear.

### *Study selection*

The primary goal of this study was to determine whether bevacizumab contributes to the development of ATE in cancer patients. Therefore, we selected only those RCTs that directly compared patients with cancer treated with and without bevacizumab. Phase I and single-arm phase II trials were excluded due to their lack of control groups. Specifically, clinical trials that met the following criteria were included in the meta-analysis: prospective phase II and III RCTs in patients with cancer; random assignment of participants to bevacizumab treatment or control (placebo or best supportive care) in addition to concurrent chemotherapy and/or biological agent; and available data including event or incidence of arterial thrombosis and sample size. Quality was assessed using criteria including adequate blinding of randomization, completeness of follow-up, and objectivity of outcome measurements as described previously [13].

### *Data extraction and clinical endpoints*

We extracted details about the number of patients, type of cancer being treated, treatment information, grading criteria for adverse events, results, follow-up, and funding or support from the included studies. Data regarding the occurrence of ATE was obtained from the safety profile of each study. Two authors (VR and SW) extracted the data independently, and any discrepancies between the authors were resolved by consensus. As summarized in Table I, ATE in these studies was assessed and recorded according to the National Cancer Institute’s common terminology criteria for adverse events (version 1, 2 or 3), which has been widely used in cancer clinical trials [14,15]. There is minor variation among these versions in grading ATE. It was graded from 1 to 4 in version 1, and from 1 to 5 in versions 2 or 3; for the study, we simply separated ATE into all grades and high grades (grade 3 and above) for our analysis. Most studies only reported high grade events.

### *Statistical analysis*

Version 2 of the Comprehensive Meta-Analysis program (Biostat, Englewood, NJ, USA) was used for statistical analysis. We calculated the incidence by using the number of patients with ATE and total number of patients receiving bevacizumab. The proportion of the patients with ATE and exact 95% CI were derived from each study. To calculate relative risk (RR), patients assigned to bevacizumab were compared only with those assigned to the control group in the same clinical trial. We explored a dose-effect relationship by further dividing bevacizumab

Table I. National Cancer Institute’s common terminology criteria versions 1-3 for arterial thromboembolic events.

Grade	Version 1	Version 2	Version 3
1	<b>Cardiac:</b> non-specific T wave flattening or changes <b>CNS:</b> none. <b>Peripheral and visceral artery:</b> none.	<b>Cardiac:</b> Non-specific T wave flattening or changes, Troponin $\geq 0.03 - < 0.05$ <b>CNS:</b> none. <b>Peripheral and visceral artery:</b> none.	<b>Cardiac:</b> Asymptomatic. Arterial narrowing no ischemia, Troponin $\geq 0.03 - < 0.05$ <b>CNS:</b> none. <b>Peripheral and visceral artery:</b> none.
2	<b>Cardiac:</b> asymptomatic ST-T changes s/o ischemia <b>CNS:</b> none <b>Peripheral and visceral artery:</b> none.	<b>Cardiac:</b> Asymptomatic ST-T changes s/o ischemia, Troponin $\geq 0.05 - < 0.1$ <b>CNS:</b> none. <b>Peripheral and visceral artery:</b> Brief episode, no surgery	<b>Cardiac:</b> Stable Angina Troponin $\geq 0.05 - < 0.1$ <b>CNS:</b> none. <b>Peripheral and visceral artery:</b> brief episode, no surgery
3	<b>Cardiac:</b> angina without infarction <b>CNS:</b> none <b>Peripheral and visceral artery:</b> none	<b>Cardiac:</b> Angina without infarction, Troponin $\geq 0.1 - < 0.2$ <b>CNS:</b> Transient ischemic attack (TIA) <b>Peripheral and visceral artery:</b> requires surgery	<b>Cardiac:</b> Unstable angina, Troponin $\geq 0.1 - < 0.2$ <b>CNS:</b> transient ischemic attack (TIA) <b>Peripheral and visceral artery:</b> requires surgery
4	<b>Cardiac:</b> acute myocardial infarction <b>CNS:</b> none <b>Peripheral and visceral artery:</b> none	<b>Cardiac:</b> Acute MI, troponin $\geq 0.2$ <b>CNS:</b> Permanent Stroke <b>Peripheral and visceral artery:</b> life – threatening or with permanent functional deficit	<b>Cardiac:</b> Acute MI, troponin $\geq 0.2$ <b>CNS:</b> Permanent Stroke <b>Peripheral and visceral artery:</b> life – threatening or with permanent functional deficit
5	None	Death	Death

Abbreviations: CNS, central nervous system; MI, myocardial Infarction; n/a, not applicable

therapy into low dose (5 or 7 · 5 mg/kg per dose per schedule, which is equivalent to 2 · 5 mg/kg per week) and high dose (10 or 15 mg/kg per dose per schedule, which is equivalent to 5 mg/kg per week). The low-dose and high-dose designation was arbitrary. Our previous studies have shown the dose-independent risk of venous thromboembolism, dose-dependent risk of hypertension or gastrointestinal perforation with bevacizumab at these dose levels [16–18].

For the meta-analysis, we used a fixed-effects (weighted with inverse variance) or random-effects model based on the heterogeneity of included studies [19]. For each meta-analysis, the Cochran’s *Q* statistic and *I*<sup>2</sup> statistics were first calculated to assess the heterogeneity among the proportions of the included trials. If the p-value was less than 0.10, the assumption of homogeneity was deemed invalid, and the random-effects model was reported after exploring the causes of heterogeneity [20]. When results of the two models were substantially different, the random-effects model was presented. Otherwise, the fixed-effects model was reported.

**Results**

*Search results and study quality*

Our search yielded 132 potentially relevant clinical studies. After excluding ineligible studies, we selected 20 RCTs, including six phase II and 14 phase III

studies for the purpose of analysis (see Figure 1 for selection process). Patients were enrolled according to pre-specified eligibility criteria for each trial. Randomized treatment allocation sequences were generated in all trials. Six trials were double-blinded and placebo controlled [7,8,21–24]; five other trials had placebo as controls [25–29]; the rest of the trials had active controls [6,30–37]. The data for three studies [11,28,37] were obtained from the published pooled analysis study [12].

ATE was assessed and recorded according to NCI-CTC versions 1, 2 or 3. Version 1 was used only in two trials [27,28], version 2 was used in eight trials [11,29–31,34–37]; version 3 was used in six trials [6,21–23,26,32]; the rest of the trials did not specify. Follow-up time was not specified in three trials [23, 32,33]. The quality of all the trials was acceptable.

*Publication bias*

We used the Begg’s and Egger’s tests to determine the presence of publication bias regarding our primary endpoint (relative risk of ATE). The two-tailed p-values were 0.92 and 0.11 for Begg’s and Egger’s tests respectively. Thus, no publication bias was detected.

*Patients*

A total of 12 617 patients from 20 RCTs were included for analysis. The characteristics of patients




Figure 1. Selection process for randomized controlled trials (RCTs) included in the meta-analysis.

and studies are listed in Table II. The baseline Eastern Cooperative Oncology Group (ECOG) performance status for most patients was between 0 and 1. Patients were required to have adequate hepatic, renal, and hematologic function. If patients had significant cardiovascular disease, peripheral vascular disease, uncontrolled HTN, serious non-healing wounds, major surgery within previous 28 days, pre-existing bleeding diathesis, brain metastasis, regular use of ASA (>325 mg/day) or non-steroidal anti-inflammatory drugs, or were pregnant, breast feeding, or were taking oral or parental anticoagulants with the exception of prophylactic anticoagulants to maintain patency of vascular device access, they were excluded from the study. Underlying malignancies included CRC (seven studies), NSCLC (four studies), breast cancer (three studies), pancreatic cancer (two studies), RCC (three studies) and malignant mesothelioma (one study). In all trials, patients were randomly assigned to either a control or bevacizumab group, with five

three arm studies each having two bevacizumab treatment groups, in which patients received different doses of bevacizumab or combination with chemotherapeutic agents.

#### *Incidences of ATE*

A total of 1 853 patients receiving bevacizumab from eight RCTs had data for all-grade ATE for analysis (Table III). Using a random-effects model, the summary incidence of all-grade ATE was 3.3% (95% CI, 1.28–3.40).

A total of 5 558 patients from 15 RCTs who received bevacizumab had data for high-grade ATE for analysis (Table IV). The summary incidence of high-grade ATE was 2.0% (95% CI, 1.7–2.5).

Grade 5 (fatal) ATE was rare. There were total seven deaths related to bevacizumab among these studies, with five due to cerebrovascular events from two studies [22,35], and two due to myocardial infarction from two studies [21,30].

Table II. Characteristics of randomized controlled trials included in the meta-analysis.

Study Name	Trial phase	No. Enrolled	No. for Analysis	Duration of Follow-up, Median (Range), mo	Underlying malignancy	Concurrent Treatment	Bevacizumab Dose, mg/kg per wk(b)	CTC version
Allegra et al. [6], 2008	3	2 710	2 710	22.4 (NA)	Colorectal cancer	Fluorouracil, oxaliplatin, and leucovorin	2.5	3
Escudier et al. [21], 2007	3	649	641	13.3 (0–25.6)	Renal Cell Carcinoma	Interferon Alfa	5	3
Giantonio et al. [31], 2007	3	829	572	28 (NA)	Colorectal cancer	Oxaliplatin, fluorouracil, and leucovorin	5	2
Herbst et al. [36], 2007	2	122	81	15.8 (NA)	NSCLC	Docetaxel or pemetrexed	5	2
Hurwitz et al. [11], 2004	3	813	790	18.0 (NA)	Colorectal cancer	Irinotecan, bolus fluorouracil, and leucovorin	2.5	2
Johnson et al. [28], 2004	2	99	98	14.7 (NA)	NSCLC	Docetaxel or pemetrexed	2.5 or 5	1
Kabbinavar et al. [27], 2003	2	104	102	17.6 (NA)	Colorectal cancer	Fluorouracil and leucovorin	2.5 or 5	1
Kabbinavar et al. [30], 2005	2	209	204	14.8 (NA)	Colorectal cancer	Bolus fluorouracil and leucovorin	2.5	2
Karrison et al. [7], 2007	2	115	108	15.1 (NA)	Mesothelioma	Cisplatin and gemcitabine	5	NA
Kindler et al. [8], 2007	3	602	523	11.3 (NA)	Pancreatic cancer	Gemcitabine	5	NA
Miles et al. [24], 2008	3	736	736	10.2 (0-17.5)	Breast cancer	Docetaxel	2.5 or 5	NA
Miller et al. [37], 2005	3	462	445	14.8 (NA)	Breast cancer	Capecitabine	5	2
Miller et al. [34], 2007	3	722	711	25.9 (NA)	Breast cancer	Paclitaxel	5	2
Price et al. [33], 2008	3	400	400	NA	Colorectal cancer	Capecitabine or mitomycin	2.5	NA
Reck et al. [23], Jco, 2009	3	1 043	986	NA	NSCLC	Cisplatin and gemcitabine	2.5 or 5	3
Rini et al. [32], 2008	3	732	715	NA	Renal Cell Carcinoma	Interferon Alfa	5	3
Saltz et al. [26], 2008	3	1 401	1 369	27.6 (NA)	Colorectal cancer	Oxaliplatin, fluorouracil, and leucovorin or capecitabine and oxaliplatin	2.5	3
Sandler et al. [35], 2006	3	878	868	19.0 (NA)	NSCLC	Paclitaxel and carboplatin	5	2
Van Cutsem et al. [22], 2009	3	607	583	6.7 (NA)	Pancreatic cancer	Gemcitabine and erlotinib	2.5	3
Yang et al. [29], 2003	2	116	116	27	Renal Cell Carcinoma	None	2.5 or 5	2.0

Abbreviations and notes: NA, data not available; NSCLC, non-small cell lung carcinoma.

(a) Funding sources: Seven trials were sponsored by Genentech [11,27,28,30,34,36,37]. Five trials were sponsored by Hoffman-LaRoche [21–24,26]. Seven trials were supported by National Cancer Institute and National Institute of Health [6,8,29,31,32,34,35]. One trial was supported by Mesothelioma Applied Research Foundation [7]. One trial was supported by Australian Gastrointestinal Trials Group [33].

(b) The dose schedule was converted from mg/kg per schedule.

### Relative risk of ATE

The observed incidence of ATE associated with bevacizumab may be attributable to known or potential risk factors such as hypertension, diabetes, hyperlipidemia,

chemotherapy, or malignancy. In order to determine the particular contribution of bevacizumab to the occurrence of ATE, and to exclude the influence of confounding factors, we calculated overall relative

Table III. Incidence and relative risk (RR) of all-grade arterial thromboembolic events (ATE) with bevacizumab according to tumor types.

	No. of Studies	All-Grade ATE (No./Total No.) Bevacizumab	All-Grade ATE (No./Total No.) Control	Incidence (95% CI), %	RR (95% CI)
Overall	8	58/1 853	23/1 720	3.3 (2.0–5.6)	2.08 (1.28–3.40)
Colorectal cancer	3	33/560	11/536	6.1 (4.4–8.5)	2.79 (1.42–5.49)
Breast cancer	2	8/594	1/561	1.6 (0.8–3.2)	3.49 (0.48–25.49)
Renal Cell Carcinoma	1	5/337	2/304	1.5 (0.6–3.5)	2.26 (0.44–11.54)
NSCLC	1	3/66	1/32	4.5 (1.5–13.2)	1.46 (0.16–13.44)
Pancreatic Cancer	1	9/296	8/287	3.0 (1.6–5.7)	1.09 (0.43–2.79)

Abbreviations and notes: CI, confidence interval; NSCLC, non-small cell lung carcinoma. The incidence and RR were calculated from the trials included in this study by meta-analysis as described in the “Methods” section.

risk of ATE from these RCTs, in which a direct comparison was made between bevacizumab and a control with concurrent standard chemotherapy or biological therapy.

We combined the data of all-grade or high-grade ATE (if data for all grade not available) from each RCT, and performed a meta-analysis to calculate the overall RR associated with bevacizumab in comparison with controls. No heterogeneity was found among these studies included in the analysis despite clear disparity in tumor type and related treatment (Figure 2). Using a fixed-effect model, the summary overall RR for bevacizumab versus control was 1.44 (95% CI 1.08–1.91,  $p=0.013$ ). Thus, there was a significantly increased risk of developing ATE in patients treated with bevacizumab. The overall risk of ATE in patients receiving bevacizumab was 44% greater than control treatment.

Also, we calculated summary RRs of all-grade and high-grade ATE with bevacizumab versus controls separately. As shown in Table III, the summary RR of all grade ATE was 2.08 (95% CI 1.28–3.40,  $p=0.003$ ) from eight RCTs, suggesting that bevacizumab significantly increased the risk of all-grade ATE by 108% when compared to a control. As shown in Table IV, the summary RR of high-grade ATE was 1.29 (95% CI 0.86–1.94,  $p = 0.21$ ) from 15 RCTs, suggesting that bevacizumab might not increase the risk of high grade ATE significantly.

*Influence of bevacizumab dose on the risk of ATE*

We explored the relationship between the dose of bevacizumab and RR of ATE to further understand the role of bevacizumab in the development of ATE. A meta-analysis was performed to calculate the relative risk associated with bevacizumab at 2.5 or 5 mg/kg/week when compared to controls. The RR of ATE for bevacizumab at 2.5 mg/kg/week was 1.52 (95% CI 1.10–2.09) from nine RCTs including 7 116 patients (bevacizumab 3 581, controls 3 535). The RR of ATE at 5 mg/kg/week was 1.50 (95% CI 0.84–2.69) from 13 RCTs including 5 061 patients (bevacizumab 3 027, controls 2 934). Therefore, both high and low doses of bevacizumab increased the risk of ATE at a similar level.

Table IV. Incidence and relative risk (RR) of high-grade arterial thromboembolic events (ATE) with bevacizumab according to tumor types.

	No. of Studies	High-Grade ATE (No./Total No.) Bevacizumab	High-Grade ATE (No./Total No.) Control	Incidence (95% CI), %	RR (95% CI)
Overall	15	98/5 558	60/4 812	2.0 (1.7–2.5)	1.29 (0.86–1.94)
Colorectal Cancer	5	47/2 531	27/2 472	1.9 (1.4–2.5)	1.57 (0.98–2.53)
Colorectal Cancer-metastatic	4	22/1 205	8/1 151	1.9 (1.2–2.8)	2.18 (0.99–4.80)
Renal cell cancer	3	16/779	2/693	2.2 (1.4–3.6)	5.14 (1.35–19.64)
NSCLC	3	20/1 125	16/809	11.3 (4.7–24.8)	0.64 (0.34–1.22)
Pancreatic Cancer	2	14/573	14/550	2.5 (1.5–4.1)	0.96 (0.46–2.0)
Breast Cancer	1	0/497	1/233	1.0 (0–1.6)	0.18 (0.01–3.83)
Malignant Mesothelioma	1	1/53	0/55	1.9 (0.3–12.2)	3.11 (0.13–74.72)

Abbreviations and notes: CI, confidence interval; NSCLC, non-small cell lung carcinoma. The incidence and RR were calculated from the trials included in this study by meta-analysis as described in the “Methods” section.

### RR of All Arterial Thromboembolic Events




Figure 2. Relative risk (RR) of arterial thromboembolic events (ATE) associated with bevacizumab versus controls. Overall summary RR of ATE was calculated using a fixed-effects model. RR for each study is displayed numerically on the left and graphically on the right. Total events and sample sizes are also displayed for each study. For study name, the first author’s name was used to represent each trial. If the same first author was involved in two trials, then the publication year was also included to identify the trial. For each trial the position of the square denoted incidence, horizontal lines represent 95% CI, and diamond plot represents overall results of the included trials. The size of the squares is directly proportional to the amount of data in each trial.

#### Risk of ATE and tumor type

In order to investigate the relationship between ATE and tumor type, we determined the risk of ATE with bevacizumab according to tumor histology. The incidence and RR of all-grade ATE varied with different tumors (Table III). The highest incidence of all-grade ATE was found in patients with CRC (6.1%, 95% CI, 4.4–8.5). Bevacizumab was also found to significantly increase the risk of all-grade ATE in patients with CRC (RR, 2.79, 95% CI 1.42–5.49, p=0.001) compared with controls.

The risk of high-grade ATE also varied with different tumors. Higher incidences of high-grade ATE were observed in patients with NSCLC, pancreatic cancer, and RCC (Table IV). Bevacizumab was

found to significantly increase the risk of high-grade ATE in patients with RCC (RR, 5.14, 95% CI 1.35–19.64, p=0.029) in comparison with controls.

#### Risk of cardiac ischemia and stroke

We also determined the risk of ATE separately according to anatomic sites of arteries (Table V). Cardiac ischemia and stroke were the two main events for ATE. Five studies were available for analysis to calculate incidence and RR of cardiac events and stroke (Figure 3). The summary incidence of high-grade cardiac ischemia was 1.5% (95% CI, 1.0–2.1%) among 2 322 patients receiving bevacizumab [29]. The summary RR of developing high-grade cardiac

Table V. Incidence and Relative Risk (RR) of arterial thromboembolic events (ATE) with bevacizumab according to organs.

ATE	No. of Studies	All-Grade thrombosis (No./Total No.)		Incidence (95% CI), %	RR (95% CI)
		Bevacizumab	Control		
Cardiac	5	33/2 322	12/2 151	1.5 (1–2.1)	2.14 (1.12–4.08)
CNS (Stroke)	5	20/2 288	13/2 253	1.2 (0.8–1.9)	1.37 (0.67–2.79)
Extremities (Peripheral)	1	0/1 326	3/1 321	0 (0–0.6)	0.14 (0.01–2.75)
Viscera	1	1/67	0/35	0.4 (0.1–2.1)	3.71 (0.20–69.79)

Abbreviations and notes: CI, confidence interval; RR, relative risk, N/A: not applicable, NSCLC, non-small cell lung carcinoma. The incidence and RR were calculated from the trials included in this study by meta-analysis as described in the “Methods” section.




Figure 3. Relative risk (RR) of cardiac ischemia or stroke associated with bevacizumab versus controls. Overall summary RRs of high grade cardiac ischemic events (A) or stroke (B) were calculated using a fixed-effects model. RR for each study is displayed numerically on the left and graphically on the right. Total events and sample sizes are also displayed for each study. For study name, the first author's name was used to represent each trial. If the same first author was involved in two trials, then the publication year was also included to identify the trial. For each trial the position of the square denoted incidence, horizontal lines represent 95% CI, and diamond plot represents overall results of the included trials. The size of the squares is directly proportional to the amount of data in each trial.

ischemia with bevacizumab versus controls was 2.14 (95% CI, 1.12–4.08, p=0.021, Figure 3A), suggesting that bevacizumab significantly increased the risk of high-grade cardiac ischemia by 114%.

The summary incidence of ischemic stroke was 1.2% (95% CI: 0.8–1.9%) among 2 288 patients receiving bevacizumab from five RCTs, with the highest being 6.3% in one study [27]. The summary RR of developing stroke with bevacizumab was 1.37 (95% CI 0.67–2.79, p=0.391) compared with controls (Figure 3B), suggesting no significant difference between bevacizumab and controls in the risk of stroke.

### Discussion

This study showed that bevacizumab significantly increased the risk of developing ATE (RR: 1.58, 95% CI 1.09–2.28) in patients with a wide variety of advanced solid tumors from a meta-analysis of 20 RCTs, consistent with a previous pooled analysis of five RCTs [12]. In addition, we showed that bevacizumab significantly increased the risk of cardiac ischemic events (RR: 2.14, 95% CI, 1.12–4.08, p=0.021).

As bevacizumab is used extensively in routine cancer treatment and clinical trials, it is important for physicians to recognize the risk of ATE including cardiac ischemia associated with bevacizumab therapy, particularly in patients with pre-existing coronary cardiac disease. Further studies are recommended to determine risk factors and underlying mechanisms for risk reduction.

The role of bevacizumab in the development of ATE is not clear. The hallmark behind any ATE is the instability of atherosclerotic plaque and the associated activation of platelets. Bevacizumab may decrease an anti-inflammatory effect of chronic VEGF exposure, thus increasing the inflammation and atherosclerotic instability, leading to plaque rupture, platelet activation, and in situ thrombus formation [38,39]. Also, VEGF is important for the repair of endothelial cells and nitrous oxide (NO) production [40]; the anti-VEGF effect of bevacizumab decreases endothelial cell renewal capacity, exposes pro-coagulant subendothelial tissue, decreases production of nitrous oxide, which is associated with vasoconstriction and increased platelet aggregation and adhesion to vascular endothelium [41–43].

Additional mechanism may include a direct activation of platelets by bevacizumab through forming complexes with VEGF on platelets, as shown by Meyer et al. in transgenic mice [44]. Finally, bevacizumab may interfere with the development of collateral circulation, a compensatory mechanism for obstructive arterial disease [45].

Our study demonstrated that the risk of ATE associated with bevacizumab varies with tumor type, with a high risk seen in patients with RCC (RR, 5.14; 95% CI, 1.35–19.64, Table IV). This variation may be related to multiple factors such as patient characteristics, tumor biology, and concurrent treatment. One possible explanation is that various ATE effects of bevacizumab may be affected by pretreatment VEGF levels in such patients; a higher level of VEGF may increase intra-plaque angiogenesis and thus predispose atherosclerotic plaque more dependent on VEGF for its stability. It was shown that the level of VEGF was highest in patients with RCC in comparison with other cancers [46]. Another study demonstrated very high levels of VEGF among RCC patients [47]. In contrast, a very low level of VEGF was observed in patients with breast cancer [48].

Our study showed that the risk of ATE did not vary with the dose of bevacizumab; RRs were 1.52 (95% CI, 1.10–2.09) and 1.50 (95% CI, 0.84–2.69) for bevacizumab at 2.5 and 5.0 mg/kg/week respectively. A lack of dose-effect relationship suggests that the low dose bevacizumab may be already reaching the saturation level to induce ATE; alternatively, the difference in effect may be too small to be detected. Interestingly, there was also no relationship between bevacizumab dose and the risk of venous thromboembolism, as shown by us previously [17], suggesting that a similar mechanism involving anti-VEGF effect might exist underlying both arterial and venous thromboembolic events associated with bevacizumab.

This study showed that bevacizumab may increase the risk of ATE differentially according to the anatomic location of arteries. Based on the available data from five RCTs (Figure 3), bevacizumab was associated with significantly increased risk of cardiac ischemia with an RR of 2.14 (95% CI, 1.12–4.08,  $p=0.021$ ), but not stroke with an RR of 1.37 (95% CI, 0.67–2.79,  $p=0.39$ ). This result suggests a possibility that bevacizumab may preferentially increase the risk of cardiac ischemic events. This could be the result of more prevalent atherosclerotic diseases in coronary arteries than in cerebral arteries; alternatively, coronary arteries may be more dependent on VEGF than cerebral arteries in maintaining vascular integrity, thus more prone to anti-VEGF treatment.

ATE may be a class-effect of angiogenesis inhibitors. Thalidomide, a potent anti-angiogenic agent blocking the action of VEGF and basic fibroblast

growth factor, is associated with the occurrence of ATE, as reported in many case series [49–51]. Sorafenib, an inhibitor of VEGF receptor (VEGFR), is associated with increased incidence of myocardial infarction compared to placebo in patients with hepatic cellular cancer or RCC [52,53]. Cardiovascular toxicity including acute coronary syndrome was also observed in patients treated with sunitinib, another inhibitor of VEGFR [54]. Caution should be taken for an increased risk of ATE when these angiogenesis inhibitors are combined to enhance anti-tumor activity.

Prevention of ATE should be considered in high-risk patients receiving bevacizumab, including age old than 65 and a history of prior ATE [12], or patients with CRC or RCC according to our study. The use of ASA, which did not significantly increase the risk of bleeding [12], should be considered in these patients if they do not have contraindications.

Our study has several limitations. Firstly, three versions of NCI-CTC were used to grade adverse events, and may have inconsistency in reported events of ATE. However, 18 of 20 studies used versions 2 and 3, which are very similar. In addition, the significance of low-grade events (grade 1–2) is not clear, and baseline cardiovascular condition was not specified. Secondly, all the studies were conducted at various institutions, and the ability to detect an ATE can vary among the institutions, which could result in potential bias of recording adverse events. However, the reported incidences of ATE are relatively similar across these studies; in addition, the calculation of RRs may reduce inherent bias within each study, and RRs reported by all of the studies were remarkably non-heterogeneous. Thirdly, these studies were conducted at academic centers and major research institutions, and patients in these clinical trials had adequate major organ function, which may not reflect general patient population in a community or patients with organ dysfunctions. Fourthly, there could be a potential observation time bias because bevacizumab is often associated with prolonged progression-free survival. However, most ATE events occurred in the early phase of treatment; the median time to the first event was 2.6 months in the bevacizumab-treated group versus 2.1 months in the control group [12]. Finally, this is a meta-analysis at the study level, so confounding factors and specific risk factors at the patient level cannot be assessed, and incorporated into the analysis.

In conclusion, the addition of the commonly used angiogenesis inhibitor bevacizumab to standard anti-neoplastic therapy significantly increased the risk of ATE particularly cardiac ischemia in cancer patients. The risk is similarly increased in patients receiving both low and high doses of bevacizumab, and may

vary with tumor type, with higher risks being associated with RCC or CRC. It is important for physicians and patients to recognize the cardiovascular side effect with bevacizumab. Future studies are recommended to investigate risk reduction.

### Acknowledgements

Shenhong Wu is partially supported by the Research Foundation of SUNY. Shenhong Wu received honoraria from Onyx Pharmaceuticals, Novartis, and Wyeth, and a speaker for Onyx, Pfizer, and Novartis. Shenhong Wu had full access to all of the data in the study, and takes responsibility for the integrity of the data and the accuracy of the data analysis.

**Declaration of interest:** The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

### References

- [1] Cavallaro U, Christofori G. Molecular mechanisms of tumor angiogenesis and tumor progression. *J Neurooncol* 2000; 50:63–70.
- [2] Folkman J. Role of angiogenesis in tumor growth and metastasis. *Semin Oncol* 2002;29(6 Suppl 16):15–8.
- [3] Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. *J Clin Oncol* 2005;23:1011–27.
- [4] Gerber HP, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. *Cancer Res* 2005; 65:671–80.
- [5] Genentech BioOncology. Avastin (bevacizumab), product insert. Last accessed on June, 2009 [cited; Available from: <http://www.gene.com/gene/products/information/pdf/avastin-prescribing.pdf>
- [6] Allegra CJ, Yothers G, O'Connell MJ, Sharif S, Colangelo LH, Lopa SH, et al. Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. *J Clin Oncol* 2009; 27:3385–90.
- [7] Karrison T, Kindler HL, Gandara DR, Lu C, Guterz TL, Nichols K, et al. Final analysis of a multi-center, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo (P) in patients (pts) with malignant mesothelioma (MM). *ASCO Meeting Abstracts* 2007;25(18 Suppl):7526.
- [8] Kindler HL, Niedzwiecki D, Hollis D, Oraefo E, Schrag D, Hurwitz H, et al. A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): A preliminary analysis of Cancer and Leukemia Group B (CALGB). *ASCO Meeting Abstracts* 2007;25(18 Suppl):4508.
- [9] Gruenberger B, Tamandl D, Schueller J, Scheithauer W, Zielinski C, Herbst F, et al. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. *J Clin Oncol* 2008;26:1830–5.
- [10] Gordon MS, Cunningham D. Managing patients treated with bevacizumab combination therapy. *Oncology* 2005; 69(Suppl 3):25–33.
- [11] Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. *N Engl J Med* 2004;350:2335–42.
- [12] Scappaticci FA, Skillings JR, Holden SN, Gerber HP, Miller K, Kabbinar F, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. *J Natl Cancer Inst* 2007; 99:1232–9.
- [13] Meade MO, Richardson WS. Selecting and appraising studies for a systematic review. *Ann Intern Med* 1997;127:531–7.
- [14] National Cancer institute's common toxicity criteria (version 2). Last accessed on March, 2009. 1999 [cited; Available from: [http://ctep.cancer.gov/forms/CTCv20\\_4-30-992.pdf](http://ctep.cancer.gov/forms/CTCv20_4-30-992.pdf)
- [15] National Cancer institute's common toxicity criteria (version 3). Last accessed on March, 2009. 2006 [cited; Available from: <http://ctep.cancer.gov/forms/CTCAEv3.pdf>
- [16] Hapani S, Chu D, Wu S. Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: A meta-analysis. *Lancet Oncol* 2009;10:559–68.
- [17] Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: A meta-analysis. *JAMA* 2008;300:2277–85.
- [18] Zhu X, Wu S, Dahut WL, Parikh CR. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: Systematic review and meta-analysis. *Am J Kidney Dis* 2007;49:186–93.
- [19] DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials* 1986;7:177–88.
- [20] Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. *Ann Intern Med* 1997;127:820–6.
- [21] Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylak C, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial. *Lancet* 2007;370(9605): 2103–11.
- [22] Van Cutsem E, Vervenne WL, Bannoun J, Humblet Y, Gill S, Van Laethem JL, et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. *J Clin Oncol* 2009;27:2231–7.
- [23] Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAIL. *J Clin Oncol* 2009;27:1227–34.
- [24] Miles D, Chan A, Romieu G, Dirix LY, Cortes J, Pivot X, et al. Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO. *ASCO Meeting Abstracts* 2008;26(15 Suppl):LBA1011.
- [25] Hurwitz HI, Fehrenbacher L, Hainsworth JD, Heim W, Berlin J, Holmgren E, et al. Bevacizumab in combination with fluorouracil and leucovorin: An active regimen for first-line metastatic colorectal cancer. *J Clin Oncol* 2005;23:3502–8.
- [26] Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. *J Clin Oncol* 2008;26:2013–9.
- [27] Kabbinar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin

- (LV) with FU/LV alone in patients with metastatic colorectal cancer. *J Clin Oncol* 2003;21:60–5.
- [28] Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. *J Clin Oncol* 2004;22:2184–91.
- [29] Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. *N Engl J Med* 2003;349:427–34.
- [30] Kabbinavar FF, Schulz J, McCleod M, Patel T, Hamm JT, Hecht JR, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: Results of a randomized phase II trial. *J Clin Oncol* 2005; 23:3697–705.
- [31] Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200. *J Clin Oncol* 2007;25:1539–44.
- [32] Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Ou SS, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. *J Clin Oncol* 2008;26: 5422–8.
- [33] Price TJ, GebSKI V, van Hazel GA, Robinson BA, Broad A, Ganju V, et al. International multi-centre randomised Phase II/III study of Capecitabine (Cap), bevacizumab (Bev) and mitomycin C (MMC) as first-line treatment for metastatic colorectal cancer (mCRC): Final safety analysis of the AGITG MAX trial. *ASCO Meeting Abstracts* 2008;26 (15 Suppl):4029.
- [34] Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. *N Engl J Med* 2007;357: 2666–76.
- [35] Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. *N Engl J Med* 2006;355: 2542–50.
- [36] Herbst RS, O'Neill VJ, Fehrenbacher L, Belani CP, Bonomi PD, Hart L, et al. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. *J Clin Oncol* 2007;25: 4743–50.
- [37] Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. *J Clin Oncol* 2005;23:792–9.
- [38] Kuenen BC, Levi M, Meijers JC, Kakkar AK, van Hinsbergh VW, Kostense PJ, et al. Analysis of coagulation cascade and endothelial cell activation during inhibition of vascular endothelial growth factor/vascular endothelial growth factor receptor pathway in cancer patients. *Arterioscler Thromb Vasc Biol* 2002;22:1500–5.
- [39] Hesser BA, Liang XH, Camenisch G, Yang S, Lewin DA, Scheller R, et al. Down syndrome critical region protein 1 (DSCR1), a novel VEGF target gene that regulates expression of inflammatory markers on activated endothelial cells. *Blood* 2004;104:149–58.
- [40] Zachary I. Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor. *Am J Physiol Cell Physiol* 2001;280:C1375–86.
- [41] Kilickap S, Abali H, Celik I. Bevacizumab, bleeding, thrombosis, and warfarin. *J Clin Oncol* 2003;21:3542; author reply 3.
- [42] Yao SK, Ober JC, Krishnaswami A, Ferguson JJ, Anderson HV, Golino P, et al. Endogenous nitric oxide protects against platelet aggregation and cyclic flow variations in stenosed and endothelium-injured arteries. *Circulation* 1992;86: 1302–9.
- [43] de Graaf JC, Banga JD, Moncada S, Palmer RM, de Groot PG, Sixma JJ. Nitric oxide functions as an inhibitor of platelet adhesion under flow conditions. *Circulation* 1992;85: 2284–90.
- [44] Meyer T, Robles-Carrillo L, Robson T, Langer F, Desai H, Davila M, et al. Bevacizumab immune complexes activate platelets and induce thrombosis in FcγR2A transgenic mice. *J Thromb Haemost* 2009;7:171–81.
- [45] Pereg D, Lishner M. Bevacizumab treatment for cancer patients with cardiovascular disease: A double edged sword? *Eur Heart J* 2008;29:2325–6.
- [46] Bando H, Brokelmann M, Toi M, Alitalo K, Sleeman JP, Sipos B, et al. Immunodetection and quantification of vascular endothelial growth factor receptor-3 in human malignant tumor tissues. *Int J Cancer* 2004;111:184–91.
- [47] Schips L, Dalpiaz O, Lipsky K, Langner C, Rehak P, Puerstner P, et al. Serum levels of vascular endothelial growth factor (VEGF) and endostatin in renal cell carcinoma patients compared to a control group. *Eur Urol* 2007;51: 168–73; Discussion 74.
- [48] Weich HA, Bando H, Brokelmann M, Baumann P, Toi M, Barleon B, et al. Quantification of vascular endothelial growth factor-C (VEGF-C) by a novel ELISA. *J Immunol Methods* 2004;285:145–55.
- [49] Alkindi S, Dennison D, Pathare A. Arterial and venous thrombotic complications with thalidomide in multiple myeloma. *Arch Med Res* 2008;39:257–8.
- [50] Scarpace SL, Hahn T, Roy H, Brown K, Paplham P, Chanan-Khan A, et al. Arterial thrombosis in four patients treated with thalidomide. *Leuk Lymphoma* 2005;46:239–42.
- [51] Altintas A, Ayyildiz O, Atay AE, Cil T, Isikdogan A, Muftuoglu E. Thalidomide-associated arterial thrombosis: Two case reports. *Ann Acad Med Singapore* 2007; 36: 304–6.
- [52] Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. *N Engl J Med* 2008;359:378–90.
- [53] Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. *N Engl J Med* 2007;356:125–34.
- [54] Schmidinger M, Zielinski CC, Vogl UM, Bojic A, Bojic M, Schukro C, et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. *J Clin Oncol* 2008;26:5204–12.